Kenneth Kalunian
Overview
Explore the profile of Kenneth Kalunian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
3559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary
Werth V, Furie R, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven R, et al.
Immunotherapy
. 2025 Feb;
:1-13.
PMID: 39995069
No abstract available.
2.
Furie R, van Vollenhoven R, Kalunian K, Navarra S, Romero-Diaz J, Werth V, et al.
Immunotherapy
. 2025 Feb;
:1-13.
PMID: 39995062
No abstract available.
3.
Askanase A, DCruz D, Kalunian K, Merrill J, Navarra S, Cahuzac C, et al.
Lancet Rheumatol
. 2024 Nov;
7(1):e21-e32.
PMID: 39586304
Background: Sphingosine-1-phosphate (S1P) is a signalling molecule that has an inhibitory role in atherosclerosis, inflammation, cell proliferation, and immunity. Cenerimod is a selective S1P receptor modulator under investigation for the...
4.
DallEra M, Kalunian K, Solomons N, Truman M, Hodge L, Yap E, et al.
Lupus Sci Med
. 2024 Nov;
11(2).
PMID: 39521453
Introduction: High-dose glucocorticoid (GC)-based dual immunosuppressive treatment regimens are still frequently used in active lupus nephritis (LN) despite their known association with dose-dependent toxicities and incomplete efficacy. We hypothesised that...
5.
Carlucci P, Preisinger K, Deonaraine K, Zaminski D, DallEra M, Gold H, et al.
Rheumatology (Oxford)
. 2024 Mar;
64(3):1193-1200.
PMID: 38530774
Objective: Lupus nephritis (LN) can occur as an isolated component of disease activity or be accompanied by diverse extrarenal manifestations. Whether isolated renal disease is sufficient to decrease health-related quality...
6.
Dhital R, Baer R, Bandoli G, Guma M, Poudel D, Kalunian K, et al.
Am J Obstet Gynecol MFM
. 2024 Mar;
6(4):101319.
PMID: 38428526
No abstract available.
7.
Izmirly P, Kim M, Carlucci P, Preisinger K, Cohen B, Deonaraine K, et al.
Arthritis Res Ther
. 2024 Feb;
26(1):54.
PMID: 38378664
Background: Leveraging the Accelerating Medicines Partnership (AMP) Lupus Nephritis (LN) dataset, we evaluated longitudinal patterns, rates, and predictors of response to standard-of-care therapy in patients with lupus nephritis. Methods: Patients...
8.
Chakravarty E, Utset T, Kamen D, Contreras G, McCune W, Aranow C, et al.
Lancet Rheumatol
. 2024 Feb;
6(3):e168-e177.
PMID: 38301682
Background: Mycophenolate mofetil is an immunosuppressant commonly used to treat systemic lupus erythematosus (SLE) and lupus nephritis. It is a known teratogen associated with significant toxicities, including an increased risk...
9.
Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke D, et al.
JCI Insight
. 2024 Jan;
9(2.
PMID: 38258904
Lupus nephritis (LN) is a pathologically heterogenous autoimmune disease linked to end-stage kidney disease and mortality. Better therapeutic strategies are needed as only 30%-40% of patients completely respond to treatment....
10.
Dhital R, Pokharel A, Karageorgiou I, Poudel D, Guma M, Kalunian K
Lupus
. 2023 Nov;
32(14):1646-1655.
PMID: 37961765
Background: Systemic lupus erythematosus (SLE) patients are prone to frequent emergency department (ED) visits. This study explores the epidemiology and outcomes of ED visits by patients with SLE utilizing the...